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 Abstract  
Being as a relatively new approach of signalling, moving-block scheme significantly increases line 
capacity, especially on congested railways. This paper describes a simulation system for multi-train 
operation under moving-block signalling scheme. The simulator can be used to calculate minimum 
headways and safety characteristics under pre-set timetables or headways and different geographic an 
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Abstract 33 
 34 
Background:  Untreated Chlamydia trachomatis infections in women can result in 35 
disease sequelae such as salpingitis and pelvic inflammatory disease (PID), ultimately 36 
culminating in tubal occlusion and infertility.  Whilst nucleic acid amplification tests 37 
can effectively diagnose uncomplicated lower genital tract (LGT) infections, they are 38 
not suitable for diagnosing upper genital tract (UGT) pathological sequelae.  As a 39 
consequence, this study aimed to identify serological markers that can, with a high 40 
degree of sensitivity and specificity, discriminate between LGT infections and UGT 41 
pathology.  Methods:  Plasma was collected from 73 women with a history of LGT 42 
infection, UGT pathology due to C. trachomatis or no serological evidence of C. 43 
trachomatis infection.  Western blotting was used to analyse antibody reactivity against 44 
extracted chlamydial proteins.  Sensitivity and specificity of differential markers were 45 
also calculated.  Results:  Four antigens (CT157, CT423, CT727 and CT396) were 46 
identified and found to be capable of discriminating between the infection and disease 47 
sequelae state.  Sensitivity and specificity calculations showed that our assay for 48 
diagnosing LGT infection had a sensitivity and specificity of 75% and 76% 49 
respectively, whilst the assay for identifying UGT pathology demonstrated 80% 50 
sensitivity and 86% specificity.  Conclusions:  The use of these assays could potentially 51 
facilitate earlier diagnoses in women suffering UGT pathology due to C. trachomatis. 52 
 53 
Key Words: Chlamydia trachomatis, pelvic inflammatory disease, serology, sensitivity, 54 
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Introduction 57 
 58 
Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen and 59 
has the ability to exist in acute or persistent states of infection.  An untreated C. 60 
trachomatis infection can result in disease sequelae such as salpingitis and pelvic 61 
inflammatory disease (PID), and ultimately lead to tubal occlusion and infertility1,2.  62 
The asymptomatic nature of chlamydial infection makes diagnosis difficult, particularly 63 
in differentiating between uncomplicated lower genital tract (LGT) infection and upper 64 
genital tract (UGT) pathology.  Current diagnostic tests for C. trachomatis have variable 65 
performance capabilities with respect to sensitivity, specificity and disease/infection 66 
stages.  The use of PCR as a diagnostic tool is limited, as specimen collection is 67 
routinely sampled from the LGT, hence infections in the fallopian tube or UGT where 68 
inflammatory damage is most significant, can escape detection.  Furthermore, PCR 69 
cannot determine whether UGT pathology may have occurred.  Serological assays aim 70 
to discriminate the various disease stages of C. trachomatis infection through 71 
identification of key antigens, however their efficacy is impeded due to cross-reactivity 72 
between chlamydial species3 and the subsequent antibody response against the target 73 
antigen is not restricted to patients with a specific stage of infection or pathology4.  74 
Consequently, several enzyme-linked immunosorbent assays have been developed that 75 
incorporate recombinant C. trachomatis antigens to improve species specificity.  The 76 
Labsystems MOMP and Medac LPS tests have the ability to diagnose C. trachomatis 77 
infection but lack the ability to identify the infection or disease status i.e. LGT infection 78 
or UGT pathology.  Furthermore, the Medac LPS assay has been reported to have low 79 
sensitivity and high cross-reactivity between chlamydial species5. 80 
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 81 
Several studies have demonstrated a correlation between antibody responses to 82 
chlamydial heat shock protein 60 (cHSP60) and pathologic sequelae in women6-8, 83 
including a significant association between the presence of antibodies to cHSP60 and 84 
PID8-10.  An association of cHSP60 antibodies and tubal factor infertility has also been 85 
reported11-13.  These observations have led to the development of a commercial ELISA 86 
screening test based on cHSP60 (Medac, Hamburg, Germany).  Studies evaluating the 87 
diagnostic potential of the Medac cHSP60 ELISA test demonstrated conflicting results 88 
and thus the ability of the cHSP60-based assay to distinguish various C. trachomatis 89 
disease stages may be limited4,14.   90 
 91 
Given the inability of current assays to reliably differentiate between uncomplicated 92 
LGT infection and UGT pathology, we undertook a serological approach to investigate 93 
novel C. trachomatis antigens that conferred increased power of discriminating between 94 
these disease states.  Samples obtained from seven patient groups with various histories 95 
of chlamydial infection (LGT – recent, previous or recurrent infection, and those with 96 
UGT – pathology/disease sequelae with evidence of chlamydial involvement), were 97 
screened using standard Western blotting techniques, to identify differential reactive 98 
antigens.  Four novel antigens showed differential antibody responses between the C. 99 
trachomatis-infected patient groups which could potentially be used to discriminate 100 
uncomplicated LGT infection and UGT pathology due to C. trachomatis.  101 
102 
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Materials and Methods 103 
 104 
Sample Collection and Patient Groups Analysed 105 
 106 
Whole blood was collected (1998 – 2002) in heparin coated vials by peripheral 107 
venipuncture.  Samples were centrifuged (15 minutes, 3000 rpm, 4ºC) and the plasma 108 
was retained and stored at -80°C.  Informed consent was obtained from all participants 109 
and the study was approved by the human ethics committees of the Queensland 110 
University of Technology, the Wesley Hospital, the Prince Charles Hospital and the 111 
Family Planning Clinic, Brisbane, Queensland, Australia.  112 
 113 
A total of 73 patients were analysed as part of this study.  Individuals were assigned to 114 
one of seven groups according to the following criteria:  115 
(a)  Group I – Females diagnosed by PCR with first-time C. trachomatis infection 116 
estimated to have been acquired within the preceding 4 months (based on sexual 117 
history) (n = 9) (Table 1);   118 
(b)  Group II – Females who had been diagnosed by PCR with first-time C. trachomatis 119 
infection more than 12 months previously (n = 11);   120 
(c)  Group III – Females with a documented history of two or more C. trachomatis 121 
infections, with the most recent diagnosed by PCR and estimated to have been acquired 122 
within the preceding 4 months (n = 4);   123 
(d)  Group IV - Females with presumptively diagnosed pelvic inflammatory disease 124 
based on clinical signs or documented history of clinical signs, a previous recorded 125 
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diagnosis of genital C. trachomatis infection or serological evidence of C. trachomatis 126 
infection (n = 10);  127 
(e)  Group V – Females diagnosed with infertility following clinical investigations, but 128 
laparoscopically show no evidence of tubal occlusion due to previous infection, have no 129 
previous documented history of PID and negative C. trachomatis serology (n = 18);  130 
(f)  Group VI – Adult females with no serological evidence for C. trachomatis infection 131 
(n = 13); and  132 
(g)  Group VII - Females aged less than 16 years with no serological evidence for C. 133 
trachomatis infection (n = 8). 134 
 135 
Groups 1 – IV patient samples were obtained from women attending either the Brisbane 136 
Sexual Health Clinic for first-time diagnosis or follow-up management of C. 137 
trachomatis infections diagnosed by urine or swab-based PCR (see below), or from the 138 
Family Planning Queensland Clinic (Brisbane, Australia).  Groups IV and V samples 139 
were obtained from women presenting to the Wesley Hospital Department of 140 
Reproductive Medicine (Brisbane, Australia) for laparoscopic and falloposcopic 141 
investigation of infertility with diagnosis based on visual findings.  Group VI samples 142 
were collected from patients attending the Brisbane Red Cross Blood Bank.  Group VII 143 
samples were obtained from stored blood specimens obtained from female children and 144 
maintained at the Queensland Medical Laboratory (Brisbane, Australia). 145 
 146 
Analysis of Chlamydial Infection  147 
 148 
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Patient samples were assayed for C. trachomatis IgG using a commercial EIA 149 
(Labsystems Chlamydia trachomatis IgG EIA) with a 1/10 dilution as per 150 
manufacturer’s instructions.  C. pneumoniae serology was determined using a 151 
commercial MIF assay (Focus Diagnostics (USA) Chlamydia MIF IgG) according to 152 
the manufacturer’s instructions.  Serology for anti-cHSP60 antibodies was performed 153 
using the Medac cHSP60-IgG-ELISA (Medac Hamburg, Germany) commercial assay 154 
according to the manufacturer’s instructions.  Samples collected at the Brisbane Sexual 155 
Health Clinic were also screened for Chlamydia infection by PCR.  First catch urine 156 
samples and genital swabs were assayed by Amplicor PCR (Roche Diagnostics) testing 157 
according to manufacturer’s instructions.  158 
 159 
C. trachomatis Cell Culture 160 
 161 
HEp-2 cells were cultured in DMEM supplemented with 5% heat-inactivated foetal calf 162 
serum and 0.002% gentamycin under 5% CO2 and infected with C. trachomatis L2 163 
strain to achieve greater than 90% confluency.  At 30 hours post-infection (pi), cultures 164 
were extracted in 3mL Laemmli sample buffer15 and stored at -20ºC until required.  In 165 
addition to the infected culture (I), HEp-2 only cells (UI) were maintained and extracted 166 
identically. 167 
 168 
Identification of Reactive C. trachomatis Proteins in Patient Samples  169 
 170 
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Patient plasma samples were compared using equivalent amounts of extracted 171 
Chlamydia/host cell proteins from UI and I HEp-2 cells.  Briefly, 10μg of extracts were 172 
separated by SDS-PAGE, transferred to Hybond C Extra nitrocellulose membranes 173 
(Amersham Biosciences).  After blocking with 5% skim milk powder in PBS containing 174 
0.1% Tween 20 (SM-PBS-T), patient plasma, diluted 1:1000 in SM-PBS-T, were 175 
incubated with the membranes at RT for 1 hour followed by horseradish peroxidise 176 
conjugated rabbit anti-human IgG (Roche).  Membranes were washed then developed 177 
using chemiluminescence (Amersham Biosciences ECL Plus Detection Kit).  The 178 
presence of bands in the I extracts that were not present in control UI extracts were 179 
recorded and used to create the differential diagnostic evaluations.   180 
 181 
Immunoprecipitation with Chlamydia-Specific Antibodies 182 
 183 
HEp-2 cell monolayers infected with C. trachomatis L2 for 24 hours were washed in 184 
cold PBS, trypsinised, lysed with 1% TritonX100 and clarified by centrifugation at 185 
12000rpm for 10 minutes at 4°C.  One mL of supernatant was mixed with 20μL patient 186 
sample and incubated at 4°C for 4 hours.  The lysate/antibody mix was next mixed with 187 
200μL buffered protein G/micro-bead suspension (Amersham Biosciences), incubated 188 
for 2 hours at 4°C and pelleted by centrifugation (6000rpm for 40 seconds). After 189 
washing thoroughly in 50mM Tris pH 7.6 (150mM NaCl, 0.1% NP40, 0.03% SDS), the 190 
pellet was suspended in Laemmli sample buffer15 in a final volume of ~100µL.  The 191 
sample was heated at 95°C for 10 minutes and stored at -20°C.  Bound proteins were 192 
separated and transferred as described for Western blotting except that Immobilon-P 193 
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polyvinylidene fluoride (PVDF) (Amersham Biosciences) membrane was used.  A 194 
segment of the membrane was reserved for Western blotting whilst the remaining 195 
membrane was stained with Coomassie blue and washed in 90% methanol.  Western 196 
blotting was performed on the membrane segment as described above.  The antigenic 197 
targets were identified by aligning Coomassie-stained membrane and western blotted 198 
membrane sections.  The differential targets were excised from the membrane and 199 
sequenced as below.   200 
 201 
N-Terminal Sequence Analysis 202 
 203 
Protein samples attached to PVDF membrane were subjected to Edman degradation 204 
(Australian Proteome Analysis Facility (APAF) at Macquarie University, Sydney) and 205 
sequences analysed using NCBI BLAST, ExPASy and The Institute for Genomic 206 
Research (TIGR) databases.   207 
 208 
Antigenic Target Identification and Verification via Mass Spectrometry 209 
 210 
Extracted chlamydial protein (I) was separated on NU-PAGE 4%-12% Bis-Tris, 1 well 211 
SDS-PAGE gels (Invitrogen) and a small slice of gel containing a section of protein was 212 
transferred to Hybond C Extra nitrocellulose membrane (Amersham Biosciences) and 213 
reserved for standard Western blotting using a single, strong-reacting patient plasma 214 
sample.  The remaining gel was Coomassie stained and aligned with the Western blot to 215 
identify antigenic targets.  Each target antigen was excised from the Coomassie gel.  216 
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Gel sections were cut into small pieces and placed into pre-washed (50% acetonitrile 217 
(ACN)/0.1% trifuluoracetic acid (TFA)) eppendorf tubes.  Each gel piece was washed 218 
twice with 200μL of 200mM NH4HCO3/50% ACN at 37°C for 45 minutes and dried .  219 
(Speedivac, Savant) on low heat for 1 hour.  Samples were taken up in 25mM 220 
NH4HCO3, reduced with 20mM dithiotreitol (DTT) for 1 hour at 65°C and then 221 
alkylated with 50mM iodoacetamide for 40 minutes at 37°C.  Gel pieces were dried and 222 
rehydrated in 25mM NH4HCO3 pH 8 containing 0.02μg/μL trypsin, and incubated at RT 223 
for 1 hour, followed by addition of two volumes of 25mM NH4HCO3/50% ACN and 224 
incubated at 37°C for 18 hours.  Peptides recovered in the supernatant were mixed with 225 
a 0.1% TFA wash of the pellet and subjected to MS analysis with results examined 226 
using Mascot software (Matrix Science). 227 
 228 
Species and Serovar Specificity 229 
 230 
To determine the species and serovar specificity of the identified antigenic targets, C. 231 
trachomatis serovars L2, D, K and C. pneumoniae were cultured in HEp-2 cells and 232 
proteins extracted as previously described.  Plasma samples from patient groups I, II 233 
and IV were screened using 12.5% SDS-PAGE gels and Western blotted against the 234 
four chlamydial protein extracts.  Protein alignments of the target antigens were 235 
performed using NCBI BLAST, ExPASy, TIGR (www.tigr.org) and Sanger Institute C. 236 
trachomatis L2 proteomic databases. 237 
 238 
Diagnostic Potential of Antigenic Targets 239 
 12 
 240 
The results obtained from the four identified target antigens were combined to evaluate 241 
their predictive potential for diagnosing the different stages of chlamydial infection.  242 
Groups I and II were combined to assess the prospect of diagnosing an uncomplicated 243 
LGT infection, whilst group IV was used to determine the potential of an assay to detect 244 
UGT pathology.  Groups V, VI, and VII served as negative controls.  Sensitivity, 245 
specificity, positive predictive value (PPV), negative predictive value (NPV) and Chi-246 
squared value (2002 Diagnostic Effectiveness Program 247 
www.quantitatieskills.com/sisa/statistics/diagnos.htm) were calculated for each 248 
individual test format.  249 
 250 
251 
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Results 252 
 253 
Immunoreactivity Patterns in Females with C. trachomatis Genital Infections 254 
 255 
Table 2 summarizes the serology and infection status for all patient groups.  Figure 1 256 
shows typical Western blot profiles when plasma from each female group were used to 257 
probe uninfected (UI) and C. trachomatis-infected (I) cell preparations.  Four bands, A 258 
(>113kDa), B (72.4kDa), C (44.6kDa) and D (13.5kDa) were differential between the 259 
patient groups (Table 3).  Of the four bands, the most commonly reactive were C (65%) 260 
and D (76%).  Band A was present in 10% of patient samples in group IV (n = 10), 261 
compared to 56%, 45% and 75% of samples in groups I (n = 9), II (n = 11) and III (n = 262 
4) respectively.  Of the 39 negative control patients tested, only one (group V) reacted 263 
with this antigen.  Band B was reactive in 75% of group III and 80% of group IV 264 
samples.  Only 8% of the negative controls reacted to band B.  Group IV samples that 265 
were reactive to band B also reacted with band C.  Of the negative control group V 266 
samples, 17% reacted to band C.  All group IV samples were reactive to band D.  In 267 
addition, 89%, 45% and 75% of samples in groups I, II and III respectively showed 268 
antibody reactivity to band D.  Antibody levels to C. pneumoniae and C. trachomatis 269 
for all groups were determined by MIF and EIA respectively prior to Western blot 270 
analysis.  The overall percentages of antibodies to C. pneumoniae ranged from 25% - 271 
55% in adults.  MIF testing showed 25% of patient samples from the control group 272 
comprising children (group VII) were positive for C. pneumoniae antibodies. 273 
 274 
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Identification and Verification of Chlamydial Antigenic Targets 275 
 276 
N-terminal sequencing yielded five to seven identifiable amino acids for each of the 277 
three bands (A, B and C) (Table 4).  NCBI BLAST searches showed band C to have 7/7 278 
matches to CT157 – Phospholipase D Endonuclease and 5/7 matches to CT423 – 279 
Cystathionine Beta Synthase (CBS) domain.  Band B showed the first five residues 280 
(DILMT) matched C. trachomatis protein CT727 – Metal transport P-type ATPase. 281 
 282 
Band A could not be identified by N-terminal sequencing as the protein was not 283 
successfully precipitated from the C. trachomatis host-cell lysate.  MS analysis of the 284 
band A sample however, identified two possible candidate proteins: CT147 (Conserved 285 
Hypothetical Protein - 162.1kDa) and CT314 (DNA-directed RNA polymerase beta 286 
chain - 154.9kDa) (Table 3).  MS analysis suggested a match of band B to CT396 287 
(HSP70 – 70.8kDa).  Band D could not be identified by either N-terminal sequencing or 288 
MS due to the limited amount of isolated protein. 289 
 290 
The amino acid sequences obtained for CT157, CT423 and CT727 are internal to the 291 
protein.  Original culture preparations of cells infected with C. trachomatis used trypsin 292 
to detach infected host cells, and thus the trypsin treatment may have cleaved the N-293 
terminal region from each of the three target antigens.  To confirm this possibility, all 294 
three protein sequences were analysed using Peptide Cutter P (ExPASy) to determine 295 
potential trypsin cleavage sites.  Potential cleavage sites for CT423 matched the results 296 
obtained by N-terminal sequencing.  In contrast, the potential cleavage sites predicted 297 
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for CT157 and CT727 were located several amino acids N-terminal of the first residue 298 
detected by the N-terminal sequencing analysis. 299 
 300 
Species and Serovar Specificity of Target Antigens  301 
 302 
Species and serovar specificity of the four antigenic targets (bands A, B, C and D) was 303 
determined by probing C. trachomatis L2, D and K, and C. pneumoniae-cell extracts 304 
with plasma samples from groups I, II and IV (Figure 2).  Group III was not included in 305 
this comparative study as all the samples from each patient were used during the initial 306 
Western blot screen.  In general, none of the four target antigens were found to be 307 
serovar or species specific (Table 5).  Moreover, patient samples serologically identified 308 
as positive for both C. trachomatis and C. pneumoniae appeared to be more highly 309 
reactive across the chlamydial serovars and species tested regardless of which group the 310 
samples were from.   311 
 312 
In each patient group, samples positive for C. trachomatis and negative for C. 313 
pneumoniae demonstrated similar antibody reactivity to the antigenic targets in 314 
comparison to the original C. trachomatis L2 extract and the D, K and C. pneumoniae 315 
protein preparations.  Bands A and B were the least reactive when samples from each of 316 
the three groups were probed against C. pneumoniae.  Group I and group II patients 317 
more commonly elicited an antibody response to bands A and B.  In contrast, patients 318 
with UGT pathology (group IV) seem to produce antibodies more frequently against 319 
bands B and C. 320 
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 321 
All four antigens showed 95% sequence conservation between homologous proteins of 322 
C. trachomatis serovars L2 and D, and C. pneumoniae.  In contrast, the level of 323 
sequence similarity amongst the C. pneumoniae proteins and their homologues in C. 324 
trachomatis varied from 9% to 87%.  CT157 showed 94% homology between C. 325 
trachomatis serovars L2 and D, whilst the C. pneumoniae protein shared only 9% 326 
sequence identity to the C. trachomatis protein.  The C. pneumoniae CT423 homologue 327 
showed 44% sequence identity to the C. trachomatis protein, which as a group, shared 328 
95% sequence homology between serovars.  A high level of sequence conservation was 329 
evident for C. trachomatis CT727 (99%) and CT396 (100%) L2 and D homologues and 330 
between species comparisons which showed 72% and 87% sequence identity for CT727 331 
and CT396 respectively. 332 
 333 
Diagnostic Potential of the Four Newly Identified Bands 334 
 335 
To discriminate between uncomplicated LGT infection and UGT pathology, the results 336 
obtained from the four identified antigens were combined into various panels and their 337 
predictive potential evaluated.  Of the 28 possible combinations, only those displaying 338 
the highest overall diagnostic potential are shown (Table 6).  Antibody response to 339 
panel format #3 (antigens A or B or C) demonstrated the greatest sensitivity (75%) and 340 
specificity (76%) compared to other potential formats for the prediction of LGT 341 
infections.  In contrast, other panel formats such as panel #1 (A + B or C) and panel #2 342 
(A + C or B) showed significantly lower sensitivities of 33% and 42% respectively, but 343 
demonstrated higher specificity (96%).  The panel 4 format (A or B or C or D) 344 
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displayed the greatest sensitivity of 79%; however the addition of antigen D when 345 
compared to the A or B or C format decreased specificity by 21%.  The removal of 346 
antigen A from the A or B or C or D panel format (i.e. to B or C or D), did not improve 347 
diagnostic discrimination; in fact, sensitivity and positive and negative predictive values 348 
were slightly reduced.  Only one combination of antigens was selected to be assessed 349 
for their predictive value in the diagnosis of UGT pathology as the initial Western blot 350 
screen of samples from group IV demonstrated 8/10 samples reacted to both B and C 351 
antigens.  As a consequence, the B + C panel format was evaluated and subsequently 352 
demonstrated 80% sensitivity and 86% specificity for the potential diagnosis of UGT 353 
pathology.   354 
 355 
Antibody Response of Identified Antigens during Stages of C. trachomatis Infection 356 
 357 
The antibody responses of bands A, B, C and D in females with histories of 358 
uncomplicated C. trachomatis infection and pathological sequelae were compared 359 
(Figure 3).  In general, antibody profiles of the antigens show a much stronger response 360 
in group III patients compared with other groups.  Furthermore, each target antigen 361 
demonstrates a decrease in the antibody response after 12 months pi (patient group II).  362 
Antigens A, B and C exhibited an identical antibody response (56%) in group I patients, 363 
whilst antibody production to antigen D is markedly increased (89%). 364 
 365 
The antibody response profile of band A suggests a moderate (56%) acute antibody 366 
response (patient group I), a slight decrease (45%) over time pi (group II patients), a 367 
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rise (75%) in those who are reinfected (patient group III) and a sharp decline in those 368 
with UGT pathology (patient group IV) due to C. trachomatis infection.  During 369 
primary infection (patient group I), moderate levels (56%) of antibodies to band B are 370 
produced and the pi phase (patient group II) shows a decrease in antibody production.  371 
The antibody profile of band C in the acute (patient group I) and pi (patient group II) 372 
stage virtually mimics that of bands A and B, however the pathological sequelae due to 373 
C. trachomatis infection (patient group IV) elicits a much stronger antibody response.  374 
Antibody levels to band D in primary infection (patient group I) elicit a much more 375 
vigorous response (89%) when compared to the acute profiles of bands A, B and C.  376 
The pi phase (patient group II) shows a rapid drop of antibodies produced to band D, 377 
whilst in patient groups III and IV, the generation of antibodies increases from 75% to 378 
100%, respectively, thus surpassing the antibody response demonstrated by patients 379 
with primary infection (group I). 380 
381 
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Discussion 382 
 383 
This study aimed to identify one or more chlamydial antigens that could be used to 384 
discriminate between uncomplicated LGT infection and UGT pathology due to C. 385 
trachomatis.  Four bands were able to distinguish between LGT infection and UGT 386 
pathology in affected women.  Two possible candidates were identified for each of 387 
bands A (CT147 and CT314), B (CT727 and CT396) and C (CT157 and CT423).   388 
 389 
Band A, reactive in 38% of C. trachomatis-infected samples was identified as two 390 
possible candidate proteins:  CT147 (Conserved Hypothetical Protein – 162.1kDa) and 391 
CT314 (DNA-directed RNA polymerase beta chain – 154.9kDa).  Only CT147 has 392 
previously been shown to elicit a humoral response as expected from the protein’s 393 
localisation to the inclusion membrane of the elementary body (EB)16.  Of the C. 394 
trachomatis-infected samples, groups I and III demonstrated the highest reactivity (56% 395 
and 75% respectively) to band A.  The alternative band A candidate, CT314, functions 396 
as a transcriptional regulator and would not be expected to be presented to the host 397 
immune system at any stage during the chlamydial developmental cycle or infection 398 
process.  Therefore, given the functional role of CT314, the probability of a humoral 399 
response targeted against this protein is unlikely. 400 
 401 
The two candidate proteins for band B are CT727 (P-type ATPase) and CT396 402 
(HSP70).  P-type ATPases constitute a superfamily of cation transport enzymes which 403 
mediate transmembrane exchange of all biologically significant cations17.  In contrast, 404 
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HSP70 is associated with outer membrane complexes of EBs and was originally thought 405 
to play a role in either attachment or entry of the EB into host cells18-19.  Although HSPs 406 
are expressed during times of stress, such as bacterial invasion, Raulston et al.20 showed 407 
that HSP70 is only exposed on the surface of purified EBs to a minor degree.  The 408 
functionality of CT396 suggests that HSP70 does indeed confer a humoral antibody 409 
response.  This is supported by comparative sequence analysis that showed CT396 is 410 
almost totally conserved between C. trachomatis and C. pneumoniae and as such, anti-411 
CT396 antibodies would be expected to demonstrate equal reactivity when probed 412 
against C. pneumoniae.  However, the latter was not the case in any of the 15 patient 413 
samples tested. 414 
 415 
One of the candidate proteins for band C, CT157, contains two phospholipase D (PLD) 416 
domains and is a member of the PLD superfamily which includes enzymes that have 417 
high catalytic activity and are involved in phospholipid metabolism.  PLDs, which are 418 
known to hydrolyse phospholipids to phosphatidic acid, may be essential for the 419 
formation of particular types of transport vesicles or be strongly involved in signal 420 
transduction21.  CT423, the second protein candidate for band C contains three 421 
functional domains (two CBS domains and one transporter-associated domain) which 422 
are implicated in intracellular targeting and trafficking as well as protein-protein 423 
interactions22.  Neither of these band C candidate proteins have previously been 424 
reported to induce a humoral response in the host, yet antibody production to one or 425 
both of these proteins was demonstrated in all but the uninfected children controls 426 
(group VII).  CT157 is the least conserved (9%) of the band C candidate proteins and 427 
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antibody reactivity for band C was shown to be greatly decreased against C. 428 
pneumoniae.  Sensitivity and specificity showed that bands B and C were not as 429 
reactive to C. pneumoniae by comparison with C. trachomatis.  Taken together, these 430 
findings suggest that the true identities of bands B and C are CT727 and CT157 431 
respectively.   432 
 433 
N-terminal sequencing of proteins isolated from bands B and C revealed sequences 434 
contained internally within CT157, CT423 and CT727.  However, the sequence 435 
DPHTSQ, which identified the protein CT423, was predicted to be cleaved by trypsin at 436 
the lysine (K) residue directly preceding the first amino acid of the identified sequence.  437 
CT157 and CT727 were cleaved three and four amino acids respectively, N-terminal to 438 
the Edman-identified sequences.  Little is known about how CT157, CT423 and CT727 439 
are intracellularly processed and it is possible that the missing amino acids were 440 
removed during maturation of the protein within the cell.  There is also a possibility that 441 
various host cell proteases may have cleaved CT157, CT423 and CT727 post-442 
translationally, thus resulting in truncated proteins.  An attempt was made to N-terminal 443 
sequence the protein isolated from band A, however Belland et al.16 showed that during 444 
immunoprecipitation, CT147 is cleaved leaving a 90kDa fragment.  If the identity of the 445 
immunoreactive band A is indeed the CT147 protein, then this would account for the 446 
inability of the approach to identify this protein as the immunoreactive band present on 447 
the PVDF membrane was excised at a molecular weight >113kDa.   448 
 449 
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Sensitivity and specificity of the identified antigens in various combinations showed the 450 
A or B or C format (panel #3) to be the most efficacious for diagnosing uncomplicated 451 
LGT infection.  The addition of antigen D to the panel (A or B or C or D) was shown to 452 
increase the sensitivity to 79%.  However, given the overall prevalence of antigen D in 453 
samples from C. trachomatis-infected patients, the diagnostic potential of antigen D for 454 
specifically identifying LGT infection is limited due to the high C. pneumoniae cross-455 
reactivity demonstrated within UGT patients.  Moreover, this suggests that antigen D 456 
could possibly be more useful as a marker of general chlamydial infection rather than of 457 
a particular stage of infection.  With a sensitivity and specificity of 80% and 86% 458 
respectively, UGT pathology could potentially be diagnosed using the B + C format.  459 
Nonetheless, a small number of women with histories of LGT infection were also 460 
reactive to bands B + C.  Therefore, future applications of this assay format should only 461 
be used as an initial screening tool supported by confirmatory investigations of greater 462 
specificity.   463 
 464 
Only one other assay for the potential diagnosis of UGT or C. trachomatis-induced 465 
sequelae is currently available, the Medac HSP60 - an assay for the detection of anti-466 
cHSP60 antibodies.  Higher anti-cHSP60 antibody responses in women with tubal 467 
pathology have been demonstrated compared to women without tubal pathology14.  468 
However, Gazzard et al.4 showed a reduction of cHSP60 reactivity in the PID/Tubal 469 
Damage group (20%) compared to patients with uncomplicated infection (28%).  In our 470 
study, anti-cHSP60 antibodies were not detected in women infected less than four 471 
months (group I), contrary to expectations.  Furthermore, the number of patient samples 472 
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from each C. trachomatis-infected group in which anti-cHSP60 antibodies were 473 
detected was only 18%, i.e. 3/38 for group II (pi) and 2/38 for groups III (multiply 474 
infected) and IV (PID).  The validity of the assay is further challenged by the detection 475 
of anti-cHSP60 antibodies in a single sample from each negative control group.  Thus, 476 
the use of the Medac HSP60 assay as an indicator of UGT pathology in our female 477 
cohort provides a sensitivity and specificity of 18% and 87% respectively which is 478 
significantly lower than the sensitivity (80%) of our newly developed B + C format.   479 
 480 
This study has some limitations centred on the small sample sizes for many of the 481 
patient cohorts and thus, prevented rigorous statistical analysis, however, the results 482 
clearly point to a powerful discriminator of LGT and UGT pathology.  In addition, 483 
despite the great care with which patients were allocated to particular sample groups, 484 
the rigor for each of the defined cohorts is uncertain given the reliance upon self-485 
reported sexual histories to determine time of infection and previous infection status.  486 
Further, in defining those women in Group IV, clinical diagnosis of PID in many cases 487 
was derived without supporting laparoscopic evidence, and the link with Chlamydia 488 
causation was circumstantial, being based on previous PCR diagnosis or more tentative 489 
serological evidence.  Selection of chlamydial strains for determining species and 490 
serovar specificity of the target antigens was limited to L2, D and K as examination of 491 
other serovars was beyond the scope of this study.  Moreover, C. trachomatis L2 was 492 
chosen as it was the primary serovar used for the duration of the study, whilst D and K 493 
strains were selected as both have the potential to cause UGT pathology, the focus of 494 
this research. 495 
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 496 
The ability to identify UGT pathology progressing from C. trachomatis infection would 497 
be a significant advance in the management of chlamydial infection or disease.  Early 498 
diagnosis of pathology or the identification of its potential onset would allow for timely 499 
interventions that could prevent serious tubal damage.  Individuals with a history or risk 500 
of multiple chlamydial infections could be monitored at each subsequent reinfection to 501 
identify the likelihood of progression to sequelae.  Furthermore, a reliable serological 502 
test for C. trachomatis-induced UGT infections could be used as a predictor of those 503 
women most likely to progress to inflammatory damage, thereby allowing for more 504 
intensely targeted preventative education to reduce risks of reinfection in this 505 
subpopulation of women.  Importantly, this study provides a diagnostic basis for a 506 
potential discriminator of LGT infection and UGT pathology. 507 
508 
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